Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel [Supporting Data]
1. STARD checklist
2. Supplementary table S1. Metadata describing origin and characteristics of designated negative controls and individuals with confirmed SARS-CoV-2 infection (provided as a separate .xlsx file).
3. Supplementary material.pdf
- Supplementary Figure S1: Sensitivity and specificity of lateral flow devices compared with RT-PCR confirmed cases and pre-pandemic controls (panels A and B) and compared with ELISA results (panels C and D).
- Supplementary Figure S2: Comparison between ELISA and LFIA for SARS-CoV-2 designated negative and positive plasma.
- Supplementary table S2. Summary grid presenting the number of samples from each cohort tested using different assay platforms.
- Supplementary table S3. Multivariable regression models for relationship between ELISA IgM and IgG readings and covariates in RT-PCR positive cases.
- Supplementary Table S4. Results of nine lateral flow immunoassays (LFIA) devices and an ELISA assay, tested with plasma classified as positive (RT-PCR positive) obtained from patients ≥10 days after onset of symptoms.
- Supplementary Table S5. Results of nine lateral flow immunoassays (LFIA) devices, tested with plasma classified as positive and negative using ELISA as an alternative reference standard (n=81-90 per LFIA device). Different manufacturers are designated A-I. 95% confidence intervals (CI) are presented for each point estimate.
4. Supplementary table S6: Results of all assays performed and relevant metadata (provided as a separate .xlsx file).